Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Optimizing treatment experience for patients with metastatic urothelial carcinoma

Enrique Grande • 22 Oct 2023
ESMO 2023
Genitourinary Cancer Urothelial Carcinoma

Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses how clinicians can optimize treatment experiences for patients with metastatic urothelial carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Enrique Grande

1:39
Emerging biomarkers of ADC response and toxicity in urothelial carcinoma
Enrique Grande • 25 Jan 2024
2:30
The future of antibody-drug conjugates in urothelial cancer
Enrique Grande • 25 Jan 2024
1:58
What’s next for antibody drug conjugates in urothelial carcinoma?
Enrique Grande • 25 Jan 2024
1:23
CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma
Enrique Grande • 25 Jan 2024

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals